top of page
Insights That Move the GPCR Field Forward
Read the latest analyses, interviews, and discoveries shaping the GPCR ecosystem — from research breakthroughs to biotech strategy.
Blog: Blog2
Search
Modulation of Striatal Adenosinergic Function by HTL0041178, a Selective GPR52 Agonist
April 2022 "By Cliona MacSweeney | Apr 20, 2022 Cliona MacSweeney, a project director in our Translational Medicine department, recently...

GPCR News
Mar 31, 20221 min read
Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization of ...
April 2022 Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization of Ultrahigh Throughput Drug...

GPCR News
Mar 31, 20221 min read
Crinetics Pharmaceuticals Announces Pricing Of Underwritten Common Stock Offering
April 2022 "SAN DIEGO, April 12, 2022 — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused...

GPCR News
Mar 31, 20221 min read
Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare ...
April 2022 Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group...

GPCR News
Mar 31, 20221 min read
Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ...
April 2022 Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with...

GPCR News
Mar 31, 20221 min read
Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage ...
April 2022 Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage of its Evolution "New team...

GPCR News
Mar 31, 20221 min read
Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with ...
April 2022 Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with Tim Dyer Addex Therapeutics...

GPCR News
Mar 31, 20221 min read
ShouTi Pharma CEO Dr. Raymond Stevens was interviewed by Moira Gunn of the NPR TechNation podcast
April 2022 Read more at the source #DrGPCR #GPCR #IndustryNews

GPCR News
Mar 31, 20221 min read
Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment ...
April 2022 Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment Of Schizophrenia & Other...

GPCR News
Mar 31, 20221 min read
Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical ...
April 2022 Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical Study "Geneva, Switzerland,...

GPCR News
Mar 31, 20221 min read
ShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary to Expand Pipeline and Partnerships
March 2022 "February 17, 2022 08:00 AM Eastern Standard Time SAN FRANCISCO & SHANGHAI- ShouTi Inc., a clinical-stage global...

GPCR News
Feb 28, 20221 min read
Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment ...
March 2022 Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment Of Neuropathic Pain "—...

GPCR News
Feb 28, 20221 min read
Addex Therapeutics To Release Full-Year 2021 Financial Results And Host Conference Call On March 10
March 2022 "Geneva, Switzerland, March 7, 2022 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company...

GPCR News
Feb 28, 20221 min read
Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B ...
March 2022 Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B Clinical Trial "MONTREAL (CANADA) –...

GPCR News
Feb 28, 20221 min read
Exscientia welcomes Richard J. Law, as their new Chief Business Officer
March 2022 "Congratulations to Richard J. Law, our newly named Chief Business Officer. Richard is the architect behind nearly all of...

GPCR News
Feb 28, 20221 min read
Domain Therapeutics and Explicyte enter partnership agreement in immuno-oncology
March 2022 "Explicyte grants Domain Therapeutics exclusivity on data related to GPCR implicated in immunoresistance, to develop first-in...

GPCR News
Feb 28, 20221 min read
Research Network on Signal Transduction (ERNEST) has established an Emergency Fund for Ukrainian ...
March 2022 ERNEST has established an Emergency Fund for Ukrainian researchers. "General Eligibility Researchers affiliated to any legal...

GPCR News
Feb 28, 20221 min read


Naggie and Rajagopal Elected Members of American Society for Clinical Investigation
March 2022 "March 3, 2022 Susanna Naggie, MD, and Sudarshan Rajagopal, MD, PhD Two School of Medicine faculty members — Susanna Naggie,...

GPCR News
Feb 28, 20221 min read
Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief ...
March 2022 Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief Commercial Officer "SAN DIEGO –...

GPCR News
Feb 28, 20221 min read


Dr. Marta Filizola - Dr. GPCR Podcast
Next on the Dr. GPCR Podcast, we have none other than Dr. Marta Filizola! Subscribe to the podcast today and get notified when new...

Dr. GPCR News
Feb 10, 20221 min read
Ermium Therapeutics has constituted its SAB
February 2022 "Ermium Therapeutics Announces the Formation of a Scientific Advisory Board comprising international leaders in GPCRs...

GPCR News
Jan 31, 20221 min read
AELIS PHARMA launches their IPO for €25 million
February 2022 "We are proud to announce the success of our IPO! Thank you to our shareholders, both historical and new, for their trust....

GPCR News
Jan 31, 20221 min read
InterAx Biotech AG and Boehringer Ingelheim take collaborate to unlock orphan targets leveraging ...
February 2022 "InterAx Biotech AG and Boehringer Ingelheim take first steps towards collaborating to unlock orphan targets leveraging...

GPCR News
Jan 31, 20221 min read
Trevena Announce Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu ...
February 2022 Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical...

GPCR News
Jan 31, 20221 min read
bottom of page

